Pre-mixed CJC-1295 and Ipamorelin in a single vial — convenient synergistic GH optimisation.
Identical mechanism to separately administered CJC-1295 (No DAC) + Ipamorelin. CJC-1295 stimulates GHRH receptors while Ipamorelin activates GHSR-1a (ghrelin receptor), producing synergistic GH pulses 2–5× larger than either peptide alone. The pre-mixed formulation ensures consistent dosing ratios.
The combination vial simplifies research protocols by eliminating the need to reconstitute and measure two separate peptides. Ipamorelin is the preferred GHRP for combination with a GHRH due to its high selectivity — it does not elevate cortisol or prolactin at standard doses.
Typically used 2–3 times daily with the most important administration being pre-sleep, coinciding with the body's largest natural GH pulse window.